Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

[1]  K. To,et al.  Serum antibody profile of a patient with COVID-19 reinfection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Kearney,et al.  Low genetic diversity may be an Achilles heel of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[3]  K. Bishop-Lilly,et al.  A Case of Early Re-infection with SARS-CoV-2 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Gieselmann,et al.  Erratum: Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients (Cell (2020) 182(4) (843–854.e12), (S0092867420308217), (10.1016/j.cell.2020.06.044)) , 2020 .

[5]  Sarah K. Hilton,et al.  Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, bioRxiv.

[6]  C. Rice,et al.  Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro , 2020, bioRxiv.

[7]  P. Maes,et al.  Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Gieselmann,et al.  Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.

[9]  Bethany L. Dearlove,et al.  A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants , 2020, Proceedings of the National Academy of Sciences.

[10]  K. To,et al.  COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  G. Ippolito,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[12]  J. Sodroski,et al.  Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.

[13]  C. Rice,et al.  Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, The Journal of experimental medicine.

[14]  Edward C. Holmes,et al.  A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.

[15]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[16]  D. Burton,et al.  Structural basis of a shared antibody response to SARS-CoV-2 , 2020, Science.

[17]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[18]  M. Nussenzweig,et al.  Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.

[19]  David Robertson,et al.  CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation , 2020 .

[20]  D. Devine,et al.  Clinical use of Convalescent Plasma in the COVID‐19 pandemic: a transfusion‐focussed gap analysis with recommendations for future research priorities , 2020, Vox sanguinis.

[21]  G. Atwal,et al.  Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.

[22]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[23]  J. Dye,et al.  Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.

[24]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[25]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[26]  L. Gieselmann,et al.  Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.

[27]  P. Bieniasz,et al.  Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients , 2020, medRxiv.

[28]  C. Rice,et al.  Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.

[29]  L. Stamatatos,et al.  Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.

[30]  Ilya J. Finkelstein,et al.  Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.

[31]  M. Nussenzweig,et al.  Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.

[32]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[33]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[34]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[35]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[36]  Qiang Zhou,et al.  A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability , 2020, bioRxiv.

[37]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[38]  F. Balloux,et al.  Emergence of genomic diversity and recurrent mutations in SARS-CoV-2 , 2020, Infection, Genetics and Evolution.

[39]  P. Kellam,et al.  The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection , 2020, The Journal of general virology.

[40]  J. Zhao,et al.  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.

[41]  Wayne T. Nicholson,et al.  Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.

[42]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[43]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[44]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[45]  M. Nussenzweig,et al.  Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir , 2019, The Journal of experimental medicine.

[46]  Raul Andino,et al.  Mapping the Evolutionary Potential of RNA Viruses. , 2018, Cell host & microbe.

[47]  Stefan Elbe,et al.  Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.

[48]  R. Sanjuán,et al.  Variation in RNA Virus Mutation Rates across Host Cells , 2014, PLoS pathogens.

[49]  R. Baric,et al.  Coronaviruses , 2011, RNA biology.

[50]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[51]  E. Holmes,et al.  Rates of evolutionary change in viruses: patterns and determinants , 2008, Nature Reviews Genetics.

[52]  S. Elena,et al.  The evolution of RNA viruses: A population genetics view. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Holland,et al.  High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus , 1989, Journal of virology.

[54]  D. Burnett.  Immunoglobulins in the lung. , 1986, Thorax.

[55]  J. Holland,et al.  Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA , 1986, Journal of virology.

[56]  R. Andino,et al.  Viral quasispecies. , 2015, Virology.